Publications by authors named "Jean-Michel Miclea"
Long-term outcome of imatinib 400 mg compared to imatinib 600 mg or imatinib 400 mg daily in combination with cytarabine or pegylated interferon alpha 2a for chronic myeloid leukaemia: results from the French SPIRIT phase III randomised trial.
Leukemia
August 2021
Article Synopsis
- - The SPIRIT trial is a long-term study that compares the effectiveness of various treatments for chronic-phase chronic myeloid leukaemia (CML), involving 787 patients followed for an average of 13.5 years.
- - Overall and progression-free survival rates after 15 years were similar across four treatment groups, ranging from 80% to 87%, suggesting comparable effectiveness of different combinations.
- - The combination of imatinib with pegylated interferon alpha2a resulted in significantly better molecular response rates compared to imatinib alone, although toxicity led to treatment cessation for some patients.
Article Synopsis
- The JAK2 mutation is crucial for diagnosing myeloproliferative neoplasms (MPN), and while qPCR is common, this study evaluates the effectiveness of next-generation sequencing (NGS) for detecting these mutations.
- Analysis of 427 patient DNA samples revealed strong agreement between qPCR and NGS when allelic burdens exceeded 2%, but NGS was less sensitive for lower burdens, missing some with qPCR values between 0.1 and 1%.
- The study identified various JAK2 variants through NGS, including a specific mutation that activates the JAK/STAT pathway, highlighting NGS as a reliable method to not only confirm mutations but also discover potentially significant new variants.
Article Synopsis
- High-dose chemotherapy with autologous stem cell transplantation is a common treatment for certain lymphoid malignancies, relying on the mobilization of hematopoietic stem and progenitor cells (HSPCs) from the bone marrow to the blood for collection via cytapheresis.
- Plerixafor, a new drug that alters the interaction between specific chemokines and their receptors, has been particularly beneficial for "poor mobilizers" who struggle to collect enough stem cells using traditional methods.
- A nationwide survey in France confirmed the effectiveness of plerixafor in improving stem cell mobilization, even for patients with limited response to other treatments, and showed that its usage was appropriate and did not
The risk of developing Hodgkin lymphoma (HL) is increased in immunodeficiencies or during the treatment of some autoimmune diseases. The development of new therapeutic agents has highlighted the risk of unusual lymphoid proliferations, particularly classical HL (cHL). We report the clinicopathological findings of 13 cHL arising in patients treated for a primary haematological malignancy.
View Article and Find Full Text PDFBackground: This report describes the specific kinetics of the peripheral blood (PB) CD34+ cell concentration in a selected group of very poor stem cell mobilizer patients treated with granulocyte-colony-stimulating factor (G-CSF) and plerixafor and determines the kinetics' impact on apheresis.
Study Design And Methods: All patients had previously experienced at least two failures of mobilization (without use of plerixafor). The present salvage therapy consisted in the administration of 10 µg/kg/day G-CSF for 5 days added to a dose of plerixafor administered at between 5 a.
Background: The ACVBP regimen is an efficient induction regimen for poor-risk patients with diffuse large B-cell lymphoma (DLBCL) before consolidative autologous stem cell transplantation. Adjunction of the monoclonal anti-CD20 antibody rituximab (R-ACVBP) was recently found to be superior to ACVBP alone. This study assessed the impact of rituximab on stem cell mobilization in two similar consecutive groups of patients treated with ACVBP in two prospective, controlled trials.
View Article and Find Full Text PDFBackground: Autologous Stem Cell Transplantation (ASCT) with Peripheral Blood Stem Cells is widely used as consolidation in lymphoma patients. The rapidity and stability of cell engraftment correlate with the number of CD34+ cells in the autograft. However, whether CD34+ cells should be quantified before or after cryopreservation remains unclear.
View Article and Find Full Text PDFA total of 138 patients whose stem cell mobilization failed following chemotherapy and granulocyte colony--stimulating factor (G-CSF) at a dose of 5 microg/kg/d were given a higher dose of G-CSF (10 microg/kg/d) for 5 days after a 7-day resting period. Stem cell mobilization was successful in 90 patients, who yielded a median of 3.5x10(6) CD34(+) cells/kg, partially successful in 17 patients (1-2.
View Article and Find Full Text PDFArticle Synopsis
- A study was conducted from 1990 to 1996 to compare different chemotherapy methods for adults with newly diagnosed acute myeloid leukemia (AML) to see which led to a better relapse-free interval (RFI).
- 592 patients were randomly assigned to three treatment arms: control "3 + 7" induction, double induction, and timed-sequential induction, with similar complete remission rates across all groups.
- In patients under 50, those receiving timed-sequential induction had a significantly improved RFI, while overall survival and event-free survival rates were comparable across all treatment arms.
In all, 625 patients with acute lymphoblastic leukemia (ALL) entered the Leucémie Aiguë Lymphoblastique de l'Adulte-94 trial from June 1994 to June 1999, and received a 4-week induction therapy followed either by chemotherapy alone or stem cell transplantation (SCT). In a clinical phase II study, 40 patients with standard- or high-risk ALL - except Philadelphia chromosome-positive ALL -, relapsing at least 3 months after the beginning of therapy and who did not receive any SCT, received a rescue protocol combining amsacrine 120 mg/m(2)/day, days 1-3, cytarabine 1 g/m(2)/12 h, days 1-5, and etoposide 100 mg/m(2)/day, days 1-5. All relapses occurred 'on therapy'.
View Article and Find Full Text PDF